Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Biologic therapy for inflammatory bowel disease comes of age.

Literature DB >> 19006611

Biologic therapy for inflammatory bowel disease comes of age.

Stephen B Hanauer.

Abstract

Entities: Disease

Year: 2008 PMID： 19006611

Source DB: PubMed Journal: Curr Gastroenterol Rep ISSN： 1522-8037

Keyword Cloud
References

× No keyword cloud information.

13 in total

1. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease.

Authors: Paul Rutgeerts; Brian G Feagan; Gary R Lichtenstein; Lloyd F Mayer; Stefan Schreiber; Jean Frederic Colombel; Daniel Rachmilewitz; Douglas C Wolf; Allan Olson; Weihang Bao; Stephen B Hanauer
Journal: Gastroenterology Date: 2004-02 Impact factor: 22.682

2. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease.

Authors: Stephen B Hanauer; Carrie L Wagner; Mohan Bala; Lloyd Mayer; Suzanne Travers; Robert H Diamond; Allan Olson; Warren Bao; Paul Rutgeerts
Journal: Clin Gastroenterol Hepatol Date: 2004-07 Impact factor: 11.382

3. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease.

Authors: Severine Vermeire; Maja Noman; Gert Van Assche; Filip Baert; Geert D'Haens; Paul Rutgeerts
Journal: Gut Date: 2007-01-17 Impact factor: 23.059

4. Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk?

Authors: Stephen B Hanauer
Journal: Gut Date: 2007-09 Impact factor: 23.059

5. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine.

Authors: A Kandiel; A G Fraser; B I Korelitz; C Brensinger; J D Lewis
Journal: Gut Date: 2005-08 Impact factor: 23.059

6. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial.

Authors: Jean-Frédéric Colombel; William J Sandborn; Paul Rutgeerts; Robert Enns; Stephen B Hanauer; Remo Panaccione; Stefan Schreiber; Dan Byczkowski; Ju Li; Jeffrey D Kent; Paul F Pollack
Journal: Gastroenterology Date: 2006-11-29 Impact factor: 22.682

Biologic therapy for inflammatory bowel disease comes of age.

1. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease.

2. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease.

3. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease.

4. Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk?

5. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine.

6. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial.

7. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease.

8. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease.

Review 9. TNFalpha blockade in human diseases: mechanisms and future directions.

10. Certolizumab pegol for the treatment of Crohn's disease.